Weekly brexpiprazole shot for acute schizophrenia flare-ups
Part of Mental health clinical trials.
This Phase 3 study tests whether a once-weekly brexpiprazole medicine can help people whose schizophrenia is currently flaring up and who need hospital-level care. It compares care for acute relapse using a longer-lasting (weekly) form of brexpiprazole.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to under 65 years old when you sign consent
- Have a confirmed schizophrenia diagnosis and your current flare started within the last 2 months
- Be in a hospital now or judged likely to need hospitalization for an acute schizophrenia relapse
- Have had recent treatment with antipsychotic medicine (not clozapine) that helped, but symptoms returned when you had a break from antipsychotics
- Be able to understand the study and sign written consent before any study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new long-acting injection of brexpiprazole, an antipsychotic that may help control schizophrenia symptoms. The study will see how the injection is absorbed, its safety, and how well people tolerate it, potentially offering a longer-lasting treatment option.
This study tests an injectable form of brexpiprazole that stays in the body for a long time. It aims to see if the shot is safe and tolerable for healthy volunteers and people with schizophrenia, and how the body processes it.
This Phase 3 study tests whether brexpiprazole can help treat bipolar depression that has not responded to previous treatments. It compares the study medicine to a placebo (inactive pill) for people with bipolar I or II depression.
This trial tests a new medication called SEP-363856 for people with schizophrenia who are currently having a severe flare-up of symptoms. It aims to see if the drug is safe and effective compared to a placebo.
This study looks at how well brexpiprazole (Rexulti) works in everyday treatment, and how people feel and function over time. You may be eligible if you’re newly started on Rexulti and have a qualifying mental health diagnosis.
This study uses brain scans (PET and MRI) to see how a specific receptor, called D3, is affected by antipsychotic medications in people with schizophrenia. You may be able to participate if you have not taken antipsychotics for at least 3 weeks and are not using nicotine products.
Hear when a new Acute Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.